Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases

NCT04729348 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04729348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04729348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
March 8, 2021
Completion date
January 17, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastasis, solid tumor, solid tumor, adult